Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma By Ogkologos - February 2, 2026 459 0 Facebook Twitter Google+ Pinterest WhatsApp Final data from the CheckMate 238 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge Adjuvant fractionated radiotherapy significantly improves DFS in patients with atypical meningioma who have undergone complete surgical resection MOST POPULAR Changing the landscape of children’s cancer treatment September 2, 2020 Clinical Trials in Genitourinary Cancers: CheckMate 914, KEYNOTE-992, and KEYNOTE-991 May 20, 2021 Workout Wednesday – Leg Stretches Part 1 July 8, 2020 A Novel Model Helps Better Predict Risk of Cancer Development in... April 15, 2024 Load more HOT NEWS Durvalumab Plus Chemotherapy Improves Survival in Small Cell Lung Cancer Efficacy and Safety of Adding Antiangiogenesis Therapy to First-Line Immunochemotherapy in... ΥΓΡΗ ΒΙΟΨΙΑ: ΤΟ ΜΕΛΛΟΝ ΣΤΗ ΔΙΑΓΝΩΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ EMA Recommends Extension of Indications for Nivolumab
